Do analysts prefer ENTO or VTGN?

VistaGen Therapeutics has a consensus target price of $0.95, indicating a potential upside of 281.68%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe VistaGen Therapeutics is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VistaGen Therapeutics 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Does the media refer more to ENTO or VTGN?

In the previous week, VistaGen Therapeutics had 4 more articles in the media than Entero Therapeutics. MarketBeat recorded 5 mentions for VistaGen Therapeutics and 1 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 0.00 beat VistaGen Therapeutics' score of -0.56 indicating that Entero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entero Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral VistaGen Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Negative

Do analysts prefer ENTO or BRNS?

Barinthus Biotherapeutics has a consensus target price of $4.00, suggesting a potential upside of 545.06%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Barinthus Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ENTO or BRNS more profitable?

Barinthus Biotherapeutics' return on equity of -63.83% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -461.02% -14.72% Barinthus Biotherapeutics N/A -63.83% -48.77%

Does the media favor ENTO or BRNS?

In the previous week, Entero Therapeutics and Entero Therapeutics both had 1 articles in the media. Entero Therapeutics' average media sentiment score of 0.00 equaled Barinthus Biotherapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entero Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Barinthus Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ENTO or DYAI?

Dyadic International has a consensus price target of $3.00, suggesting a potential upside of 218.98%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts clearly believe Dyadic International is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dyadic International 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media refer more to ENTO or DYAI?

In the previous week, Entero Therapeutics and Entero Therapeutics both had 1 articles in the media. Entero Therapeutics' average media sentiment score of 0.00 equaled Dyadic International'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entero Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ENTO or CPHI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend BCTX or ENTO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, BCTX or ENTO?

Entero Therapeutics is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$7.92 N/A Entero Therapeutics N/A N/A -$18.06M -$1.69 N/A

Is BCTX or ENTO more profitable?

Briacell Therap's return on equity of -153.53% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% Entero Therapeutics N/A -461.02% -14.72%

Entero Therapeutics (ENTO) Competitors

$4.40 -0.05 (-1.12%)

As of 07/2/2026

Compare

ENTO vs. VTGN, BRNS, DYAI, CPHI, and BCTX

Should you buy Entero Therapeutics stock or one of its competitors? MarketBeat compares Entero Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Entero Therapeutics include VistaGen Therapeutics (VTGN), Barinthus Biotherapeutics (BRNS), Dyadic International (DYAI), China Pharma (CPHI), and Briacell Therap (BCTX). These companies are all part of the "pharmaceutical products" industry.

How does Entero Therapeutics compare to VistaGen Therapeutics?

Entero Therapeutics (NASDAQ:ENTO) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Entero Therapeutics has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -5,487.01%. VistaGen Therapeutics' return on equity of -133.02% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-461.02%	-14.72%
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%

Entero Therapeutics has higher earnings, but lower revenue than VistaGen Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A
VistaGen Therapeutics	$1.27M	8.05	-$69.68M	-$1.83	N/A

Entero Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

VistaGen Therapeutics has a consensus target price of $0.95, indicating a potential upside of 281.68%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe VistaGen Therapeutics is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, VistaGen Therapeutics had 4 more articles in the media than Entero Therapeutics. MarketBeat recorded 5 mentions for VistaGen Therapeutics and 1 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 0.00 beat VistaGen Therapeutics' score of -0.56 indicating that Entero Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entero Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VistaGen Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Negative

Summary

VistaGen Therapeutics beats Entero Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Entero Therapeutics compare to Barinthus Biotherapeutics?

Entero Therapeutics (NASDAQ:ENTO) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Barinthus Biotherapeutics has a consensus target price of $4.00, suggesting a potential upside of 545.06%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Entero Therapeutics and Entero Therapeutics both had 1 articles in the media. Entero Therapeutics' average media sentiment score of 0.00 equaled Barinthus Biotherapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entero Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Barinthus Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Entero Therapeutics has higher earnings, but lower revenue than Barinthus Biotherapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A
Barinthus Biotherapeutics	$14.97M	1.69	-$66.43M	-$1.29	N/A

Barinthus Biotherapeutics' return on equity of -63.83% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-461.02%	-14.72%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Entero Therapeutics has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.41, suggesting that its share price is 141% less volatile than the broader market.

Summary

Barinthus Biotherapeutics beats Entero Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Entero Therapeutics compare to Dyadic International?

Entero Therapeutics (NASDAQ:ENTO) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

In the previous week, Entero Therapeutics and Entero Therapeutics both had 1 articles in the media. Entero Therapeutics' average media sentiment score of 0.00 equaled Dyadic International'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entero Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Entero Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Entero Therapeutics' return on equity of -461.02% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-461.02%	-14.72%
Dyadic International	-192.40%	-1,005.45%	-77.64%

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Comparatively, 20.9% of Dyadic International shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dyadic International has higher revenue and earnings than Entero Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A
Dyadic International	$3.09M	11.09	-$7.36M	-$0.23	N/A

Entero Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, Dyadic International has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

Dyadic International has a consensus price target of $3.00, suggesting a potential upside of 218.98%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts clearly believe Dyadic International is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Dyadic International beats Entero Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Entero Therapeutics compare to China Pharma?

Entero Therapeutics (NASDAQ:ENTO) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Entero Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, China Pharma has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

China Pharma has higher revenue and earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A
China Pharma	$3.99M	7.29	-$3.08M	-$0.55	N/A

12.3% of Entero Therapeutics shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Comparatively, 6.4% of China Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Entero Therapeutics had 1 more articles in the media than China Pharma. MarketBeat recorded 1 mentions for Entero Therapeutics and 0 mentions for China Pharma. Entero Therapeutics' average media sentiment score of 0.00 equaled China Pharma'saverage media sentiment score.

Company	Overall Sentiment
Entero Therapeutics	Neutral
China Pharma	Neutral

Entero Therapeutics has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-461.02%	-14.72%
China Pharma	-85.56%	-63.93%	-31.42%

Summary

Entero Therapeutics and China Pharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Entero Therapeutics compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Briacell Therap's return on equity of -153.53% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Entero Therapeutics	N/A	-461.02%	-14.72%

Briacell Therap has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Entero Therapeutics had 1 more articles in the media than Briacell Therap. MarketBeat recorded 1 mentions for Entero Therapeutics and 0 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.00 equaled Entero Therapeutics'average media sentiment score.

Company	Overall Sentiment
Briacell Therap	Neutral
Entero Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Entero Therapeutics is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A

Summary

Entero Therapeutics beats Briacell Therap on 6 of the 9 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTO vs. The Competition

Export

Metric	Entero Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.99M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-2.60	21.61	28.02	24.70
Price / Sales	N/A	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	-1.80	8.66	10.96	6.46
Net Income	-$18.06M	$23.81M	$3.57B	$337.01M
7 Day Performance	-0.23%	3.39%	2.12%	1.69%
1 Month Performance	-27.39%	10.81%	5.25%	3.81%
1 Year Performance	263.04%	62.61%	33.29%	23.90%

Entero Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTO Entero Therapeutics	0.0165 of 5 stars	$4.40 -1.1%	N/A	+263.0%	$6.99M	N/A	N/A	9	News Coverage Gap Up
VTGN VistaGen Therapeutics	2.7657 of 5 stars	$0.62 -7.3%	$0.95 +54.1%	-87.7%	$27.28M	$1.27M	N/A	40	News Coverage Gap Down
BRNS Barinthus Biotherapeutics	1.7519 of 5 stars	$0.72 +8.9%	$4.00 +456.3%	-36.4%	$26.96M	$14.97M	N/A	107	News Coverage Gap Up
DYAI Dyadic International	2.4082 of 5 stars	$0.74 +1.4%	$3.00 +304.9%	+1.0%	$26.64M	$3.09M	N/A	7	Gap Up
CPHI China Pharma	N/A	$0.66 +2.3%	N/A	-61.0%	$26.54M	$3.99M	N/A	250	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTO) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entero Therapeutics (ENTO) Competitors

ENTO vs. VTGN, BRNS, DYAI, CPHI, and BCTX

How does Entero Therapeutics compare to VistaGen Therapeutics?

Summary

How does Entero Therapeutics compare to Barinthus Biotherapeutics?

Summary

How does Entero Therapeutics compare to Dyadic International?

Summary

How does Entero Therapeutics compare to China Pharma?

Summary

How does Entero Therapeutics compare to Briacell Therap?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTO vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entero Therapeutics (ENTO) Competitors

ENTO vs. VTGN, BRNS, DYAI, CPHI, and BCTX

How does Entero Therapeutics compare to VistaGen Therapeutics?

Is ENTO or VTGN more profitable?

Which has stronger earnings and valuation, ENTO or VTGN?

Which has more risk and volatility, ENTO or VTGN?

Do insiders and institutionals believe in ENTO or VTGN?

Do analysts prefer ENTO or VTGN?

Does the media refer more to ENTO or VTGN?

Summary

How does Entero Therapeutics compare to Barinthus Biotherapeutics?

Do analysts prefer ENTO or BRNS?

Does the media favor ENTO or BRNS?

Which has better valuation and earnings, ENTO or BRNS?

Is ENTO or BRNS more profitable?

Do insiders and institutionals hold more shares of ENTO or BRNS?

Which has more volatility and risk, ENTO or BRNS?

Summary

How does Entero Therapeutics compare to Dyadic International?

Does the media refer more to ENTO or DYAI?

Is ENTO or DYAI more profitable?

Do insiders & institutionals have more ownership in ENTO or DYAI?

Which has preferable valuation & earnings, ENTO or DYAI?

Which has more risk and volatility, ENTO or DYAI?

Do analysts recommend ENTO or DYAI?

Summary

How does Entero Therapeutics compare to China Pharma?

Do analysts recommend ENTO or CPHI?

Which has more risk & volatility, ENTO or CPHI?

Which has preferable earnings and valuation, ENTO or CPHI?

Do insiders and institutionals have more ownership in ENTO or CPHI?

Does the media favor ENTO or CPHI?

Is ENTO or CPHI more profitable?

Summary

How does Entero Therapeutics compare to Briacell Therap?

Is BCTX or ENTO more profitable?

Which has more risk and volatility, BCTX or ENTO?

Do insiders & institutionals believe in BCTX or ENTO?

Does the media prefer BCTX or ENTO?

Do analysts recommend BCTX or ENTO?

Which has higher earnings and valuation, BCTX or ENTO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTO vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools